RU2017138187A - A method of reducing the hypertensive effect of cobalt chloride calcitonin - Google Patents

A method of reducing the hypertensive effect of cobalt chloride calcitonin Download PDF

Info

Publication number
RU2017138187A
RU2017138187A RU2017138187A RU2017138187A RU2017138187A RU 2017138187 A RU2017138187 A RU 2017138187A RU 2017138187 A RU2017138187 A RU 2017138187A RU 2017138187 A RU2017138187 A RU 2017138187A RU 2017138187 A RU2017138187 A RU 2017138187A
Authority
RU
Russia
Prior art keywords
cobalt chloride
calcitonin
reducing
hypertensive effect
administered
Prior art date
Application number
RU2017138187A
Other languages
Russian (ru)
Other versions
RU2699800C2 (en
RU2017138187A3 (en
Inventor
Вадим Борисович Брин
Олег Тасолтанович Кабисов
Давид Хачатурович Оганесян
Original Assignee
Федеральное государственное бюджетное образовательное учреждение высшего образования "Северо-Осетинская государственная медицинская академия" Министерства здравоохранения Российской Федерации
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Федеральное государственное бюджетное образовательное учреждение высшего образования "Северо-Осетинская государственная медицинская академия" Министерства здравоохранения Российской Федерации filed Critical Федеральное государственное бюджетное образовательное учреждение высшего образования "Северо-Осетинская государственная медицинская академия" Министерства здравоохранения Российской Федерации
Priority to RU2017138187A priority Critical patent/RU2699800C2/en
Publication of RU2017138187A publication Critical patent/RU2017138187A/en
Publication of RU2017138187A3 publication Critical patent/RU2017138187A3/ru
Application granted granted Critical
Publication of RU2699800C2 publication Critical patent/RU2699800C2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Claims (1)

Способ уменьшения гипертензивного эффекта хлорида кобальта кальцитонином, включающий ежедневное с первого дня эксперимента введение экспериментальным животным действующего вещества и хлорида кобальта подкожно, отличающийся тем, что в качестве действующего вещества применяют синтетический кальцитонин лосося, который вводят экспериментальным животным в дозе 0,6 МЕ/100 г, а хлорид кобальта вводят в дозе 0,4 мг/100 г.A method for reducing the hypertensive effect of cobalt chloride calcitonin, which includes administering the active substance and cobalt chloride to the experimental animals daily subcutaneously from the first day of the experiment, characterized in that synthetic calcitonin of salmon is administered as the active substance and administered to experimental animals at a dose of 0.6 IU / 100 g , and cobalt chloride is administered at a dose of 0.4 mg / 100 g.
RU2017138187A 2017-11-01 2017-11-01 Method for reducing hypertensive effect of cobalt chloride with calcitonin RU2699800C2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
RU2017138187A RU2699800C2 (en) 2017-11-01 2017-11-01 Method for reducing hypertensive effect of cobalt chloride with calcitonin

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2017138187A RU2699800C2 (en) 2017-11-01 2017-11-01 Method for reducing hypertensive effect of cobalt chloride with calcitonin

Publications (3)

Publication Number Publication Date
RU2017138187A true RU2017138187A (en) 2019-05-06
RU2017138187A3 RU2017138187A3 (en) 2019-05-06
RU2699800C2 RU2699800C2 (en) 2019-09-11

Family

ID=66430090

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2017138187A RU2699800C2 (en) 2017-11-01 2017-11-01 Method for reducing hypertensive effect of cobalt chloride with calcitonin

Country Status (1)

Country Link
RU (1) RU2699800C2 (en)

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2359338C1 (en) * 2008-02-20 2009-06-20 Федеральное государственное образовательное учреждение высшего профессионального образования "Чувашский государственный университет им. И.Н. Ульянова" Arterial hypertension simulation method
CN102076353A (en) * 2008-06-25 2011-05-25 诺沃-诺迪斯克有限公司 Derivatised hybrid peptides of amylin and salmon calcitonin
EP2405934B1 (en) * 2009-03-12 2014-03-26 Nordic Bioscience A/S Treatment of diabetes and metabolic syndrome
RU2455982C1 (en) * 2010-11-09 2012-07-20 Федеральное государственное бюджетное учреждение "Уральский научно-исследовательский институт дерматовенерологии и иммунопатологии" Министерства здравоохранения и социального развития Российской Федерации (ФГБУ "УрНИИДВиИ" Минздравсоцразвития России) Method of treating patients with mycosis fungoides

Also Published As

Publication number Publication date
RU2699800C2 (en) 2019-09-11
RU2017138187A3 (en) 2019-05-06

Similar Documents

Publication Publication Date Title
CY1123460T1 (en) COMPOUNDS AND METHODS FOR TREATING AN EPILEPSY DISORDER
EA201790568A1 (en) APPLICATION OF DOUBLE AGONIST OF GLP-1 / GLYCAGON RECEPTORS FOR PROLONGED ACTION FOR THE TREATMENT OF NON-ALCOHOLIC LIVER DISEASE
EA201792592A1 (en) PHARMACEUTICAL PREPARATIONS CONTAINING TENOFOVIR AND EMTRICITABIN
EA201492010A1 (en) APPLICATION OF HIGH DOSE OF LACHINIMODE FOR TREATMENT OF MULTIPLE SCLEROSIS
MX2019006773A (en) Dexmedetomidine or medetomidine for use in treating separation anxiety in dogs.
FI3383385T4 (en) Melflufen dosage regimens for cancer
EA202190429A1 (en) Bioavailable oral dosage forms
RU2014148977A (en) PROCESSING FISH POPULATION WITH LUFENURON
EA202091112A1 (en) SOCRYSTALS, PHARMACEUTICAL COMPOSITIONS BASED ON THEIR BASED AND METHODS OF TREATMENT FOR THEIR APPLICATION
RU2020120876A (en) A PHARMACEUTICAL COMPOSITION CONTAINING ANTAGONIST OF MINERALOCORTICOID RECEPTORS AND ITS APPLICATION
RU2017138187A (en) A method of reducing the hypertensive effect of cobalt chloride calcitonin
RU2015134356A (en) PEPTIDE
EA202191063A1 (en) NEW DOSE FORM
WO2016130518A3 (en) Methods and compositions for treating muscle disease and disorders
EA201791038A1 (en) TREATMENT OF INPUTABILITY OF ENTERAL FOOD
RU2014145029A (en) A method for the prevention of cancer of the liver and esophagus in laboratory animals
RU2013130302A (en) APPLICATION OF THE ADSORPED HOMOGENATE OF A NUTRITION AND VITAMIN D3 OR VITAMINS OF GROUP D, AND / OR THEIR ACTIVE METABOLITES FOR PREVENTION AND TREATMENT OF VIRAL DISEASES
EA202090416A1 (en) METHODS FOR TREATING GASTROPARESIS SYMPTOMS USING A VELUSETRAGA
RU2016139885A (en) A method for the treatment of hepatosis in cattle
MX362435B (en) Novel pharmaceutical system of biphasic delivery for treating pain and inflammation.
RU2016112560A (en) METHOD FOR IMPROVING AN ANTIOXIDANT PROTECTION SYSTEM OF ANIMAL ORGANISM
RU2014107146A (en) METHOD FOR PREVENTING A CARCINOGENIC EFFECT OF DIETHYLNITROSAMINE IN EXPERIMENTAL ANIMALS
RU2011111891A (en) METHOD FOR PREVENTION OF SYSTEMIC AMYLOIDOSIS AND ITS NEPHROPATHIC FORM IN EXPERIMENTAL ANIMALS
EA202000253A1 (en) APPLICATION OF A PHARMACEUTICAL COMPOSITION IN THE FORM OF A SOLUTION THAT CONTAINS ARGININE HYDROCHLORIDE AND LEVOCARNITIN FOR THE TREATMENT OF CORONARY HEART DISEASE
AR101227A1 (en) COMBINATIONS OF A N-TIAZOLIL-4-PHENOXIBENCENOSULFONAMIDE DERIVATIVE AND A PHARMACEUTICALLY ACTIVE AGENT SELECTED FROM GABAPENTINE AND PREGABALINE TO TREAT PAIN

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20191102